July 29, 2020 / 6:36 AM / 15 days ago

India's Hetero wins approval to launch COVID-19 drug favipiravir

BENGALURU, July 29 (Reuters) - India’s Hetero Labs Ltd said on Wednesday it received local regulatory approval to launch its version of anti-viral drug favipiravir for the treatment of COVID-19.

The drug, priced at 59 rupees (79 cents) per tablet, will be available at drug stores from Wednesday, privately held Hetero said. ($1 = 74.7800 Indian rupees) (Reporting by Sachin Ravikumar; Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below